Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

By / 04/01/2024

Medivir AB announced that Medivir’s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor.